Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets, gross, previous reporting   $ 19,860,000
Deferred tax assets, gross   21,164,000
Share-based Payment Arrangement, Expense $ 3,400,000 3,800,000
Cash equivelant maximuminsured value 250,000  
Revenue 0 20,000
External clinical studies study expens 1,600,000 1,700,000
Internal clinical studies study expens 1,000,000.0 2,000,000.0
Research and development costs offset by amortization $ 555,746 $ 0
Common shares issuable upon the exercise of outstanding stock options and warrants 7,250,206 3,120,962
Potentially dilutive securities 53,076  
Warrants   $ 953,857
Current federal deposit insurance $ 250,000  
Amortization amount attributable to related parties 150,805  
Common shares from convertible debentures and related accrued interest   974,449
R & D [Member]    
Share-based Payment Arrangement, Expense 500,000 2,900,000
SG & A [Member]    
Share-based Payment Arrangement, Expense $ 800,000 $ 3,000,000.0